No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

3/12

Emergent

BioSolutions

Rocketvax

RVX-sCPD9

RVX-OTS

RVX-13

SARS-CoV-2 Vaccine

Infectious

diseases

Covid-19

Preclinical

n/d

2

3/12

Roche

Zealand Pharma

Petrelintide

Long-acting amylin analog

Metabolic

disorder

Obesity

Phase II

5,300

3

3/12

ONO

Pharmaceutical

Ionis Pharmaceuticals

Sapablursen

TMPRSS6 ASO

Hematology

Polycythemia vera

Phase II

940

4

3/13

MeiraGTx

Hologen AI

AAV-GAD

AAV based gene therapy

Neurology

Parkinson’s disease

Phase II

430

5

3/19

Servier

Black Diamond Therapeutics

BDTX-4933

BRAF inhibitor

Oncology

Solid tumors;
RAS/RAF mut. NSCLC

Phase I

780

6

3/24

Novo Nordisk

The United Laboratories

UBT251

GLP-1/GIP/glucagon

triple receptor agonist

Metabolic

disorder

Obesity

Phase II

2,000

7

3/25

Anixa Biosciences

VERDI Solutions

-

AI guided Personalized

and off-the-shelf cancer

vaccines

Oncology

-

-

n/d

8

3/25

MSD

Jiangsu Hengrui
Pharmaceuticals Co., Ltd

HRS-5346

Lipoprotein(a) Inhibitor

Cardiovascular

Disease

Unspecified

cardiovascular Disease

Phase II

1,970

9

3/26

Bayer

Puhe BioPharma

BAY 3713372
(PH020)

MTA-cooperative PRMT5

inhibitor

Oncology

MTAP-deleted

solid tumors

Phase I

n/d

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

3/5

Jazz Pharmaceuticals

Chimerix

Dordaviprone

DRD2 antagonist,
ClpP agonist

Oncology

H3 K27M-mutant diffuse glioma

NDA
(PDUFA 8/18)

935

2

3/9

Sun Pharma

Checkpoint Therapeutics

Unloxcyt(Cosibelimab)

Olafertinib

PD-L1 mAb
EGFR T790M inhibitors

Oncology
Oncology

cSCC
NSCLC

Approved

Phase III

416

3

3/10

BioCorRx Pharmaceuticals

USWM, LLC

Lucemyra(Lofexidine)*

ADRA2 agonist

Neurology

Opioid withdrawal symptoms

Marketed

n/d

4

3/10

BMS

2seventy bio

Abecma
(Idecabtagene vicleu)

BCMA CAR-T

Oncology

Multiple myeloma

Marketed

286

5

3/17

AstraZeneca

EsoBiotec SA

ENaBL Platform

in vivo cell therapy

Oncology

-

-

1,000

6

3/17

Taiho Pharma

Araris Biotech

AraLinQ Platform

ADC linker

Oncology

Hematological and solid tumors

-

1,140

7

3/20

Paratek Pharma

Optinose

Xhance(Fluticasone propionate)*

GCCR agonist

Inflammation

Chronic rhinosinusitis (CRS)

Marketed

330

8

3/20

Sanofi

Dren Bio

DR-0201*

CD20 BsAb

Oncology

B-cell non-Hodgkin lymphoma

Phase I

1,900

9

3/27

Scinai Immuno-therapeutics Ltd

PinCell srl

PC111

mAb

Inflammation

Pemphigus,
Steven Johnson’s Syndrome,
Toxic Epidermal Necrolysis

Preclinical

n/d